Ozoralizumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Identifiers | |
| CAS Number | 1167985-17-2  |
| ATC code | none |
| Chemical data | |
| Formula | C1682H2608N472O538S12 |
| Molecular mass | 38.43 kg/mol |
 (what is this?) (verify) |
|
Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Pfizer
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
